{
    "2021-06-04": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Results from IMBRUVICAÂ® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "ibrutinib",
                        "RESONATE-2",
                        "Seven Years",
                        "Progression-Free",
                        "Overall Survival",
                        "First-Line",
                        "Chronic Lymphocytic Leukemia",
                        "CLL"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}